Burning Rock Biotech (NASDAQ:BNR) Trading 0.1% Higher – Time to Buy?

Burning Rock Biotech Limited (NASDAQ:BNR)’s stock price shot up 0.1% on Tuesday . The company traded as high as $7.39 and last traded at $7.06. 8,916 shares were traded during mid-day trading, an increase of 79% from the average session volume of 4,979 shares. The stock had previously closed at $7.05.

Burning Rock Biotech Price Performance

The firm has a market cap of $72.32 million, a PE ratio of -2.35 and a beta of 0.55. The company has a 50 day simple moving average of $5.55 and a 200-day simple moving average of $5.27.

Hedge Funds Weigh In On Burning Rock Biotech

A hedge fund recently bought a new stake in Burning Rock Biotech stock. SkyView Investment Advisors LLC acquired a new stake in Burning Rock Biotech Limited (NASDAQ:BNR) in the 2nd quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The fund acquired 10,000 shares of the company’s stock, valued at approximately $64,000. SkyView Investment Advisors LLC owned about 0.10% of Burning Rock Biotech as of its most recent filing with the Securities & Exchange Commission. 30.03% of the stock is owned by hedge funds and other institutional investors.

Burning Rock Biotech Company Profile

Burning Rock Biotech Limited primarily develops and commercializes cancer therapy selection tests in the People's Republic of China. It operates in three segments: Central Laboratory Business, In-Hospital Business, and Pharma Research and Development Services. The company primarily offers next-generation sequencing-based tissue and liquid biopsy cancer therapy selection and prognosis prediction tests for various range of cancer types, including lung cancer, gastrointestinal cancer, prostate cancer, breast cancer, lymphomas, thyroid cancer, colorectal cancer, ovarian cancer, pancreatic cancer, and bladder cancer using tissue and liquid biopsy samples.